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ABSTRACT  
 
The counterregulatory hormone glucagon normally prevents hypoglycemia (low blood glucose); 
however, recurrent hypoglycemia attenuates glucagon counterregulation to subsequent bouts of 
hypoglycemia. This attenuated response of glucagon with repeated hypoglycemic events may 
explain why patients with diabetes mellitus are at increased risk for more severe hypoglycemic 
events with time. As somatostatin normally inhibits glucagon secretion, we hypothesize that a 
somatostatin receptor type II antagonist (SSTR2a), PRL-2903, improves glucagon responses 
attenuated by recurrent hypoglycemia. Healthy male Sprague-Dawley rats (n=22) were made 
hypoglycemic on three consecutive days (blood glucose 1.7-2.2 mmol/L for ~2 h) via insulin bolus 
administration (10-, 8- and 5-U/kg of Humulin-R on days 1-3, respectively). Glucagon levels during 
hypoglycemia (blood glucose [BG] ≤ 3.5 mmol/L) on day 3 were significantly lower than on day 1 
(107±10.27 vs. 168.30±15.22 [mean±SEM] pg/mL; p=0.0035). On day 4, rats were treated with 
either SSTR2a (PRL-2903, 10 mg/kg IP; n=13) or vehicle (10 mg/kg IP; n=9) 1 h prior to the 
induction of hypoglycemia with 5 U/kg of R-insulin. Glucagon levels during hypoglycemia were 
2.5-fold higher (109.38±15.37 vs. 44±8.70 pg/mL; p=0.004) compared to vehicle, and time to 
reach hypoglycemia was 3.2-fold longer (63.85±12.48 vs. 20±3.23 min; P=0.001), with SSTR2a 
pre-treatment. Also, C-peptide levels were lower (p=0.01) with SSTR2a (0.35±0.06 ng/mL) 
compared to vehicle (0.63±0.07 ng/mL). Hepatic glycogen levels were also lower with SSTR2a 
pre-treatment compared to vehicle (11.77±1.41 vs. 20.66±2.34; p=0.001). In conclusion, our data 
suggests that SSTR2a improves glucagon responsiveness and increases hepatic glycogen 
breakdown during a hypoglycemic event in animals previously exposed to recurrent 
hypoglycemia. These findings are important in understanding the potential therapeutic benefit of 
drugs that can block somatostatin receptor 2 action in patients living with diabetes who are prone 
to recurrent hypoglycemia.  
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INTRODUCTION                                                               1   
  
Blood glucose (BG) regulation relies on an interconnected system of multiple 
organs and biochemical pathways. Both the central (hypothalamic) and peripheral 
(hormonal) counterregulatory pathways operate in a synchronized manner to maintain 
BG levels within a tight normal range (i.e. 4.0-7.0 mmol/L; 72-126 mg/dL) even during 
exercise, with short term fasting, and within a few hours after feeding in healthy 
organisms (1,2). Various sites in the body, including but not limited to the brain, portal 
vein, liver, intestines, carotid sinus, and the pancreas are sensitive to changes in BG 
levels and respond in a concerted fashion to preserve glucose homeostasis (1). This 
facilitates fast and effective whole body detection of variations in BG levels at multiple 
locations, which is required for stimulation of appropriate hormonal, and neuronal 
responses involved in glucose metabolism. In other words, in the healthy state, multiple 
interactions between nutrients, metabolites, hormones, and neurotransmitters allow for 
maintenance of BG homeostasis. Therefore, when studying normal and abnormal 
glucose homeostasis, using an in vivo animal model has advantages over cell lines or in 
vitro preparations, since the former involves the complex interactions between various 
biological and physiological systems. In studies of glucose homeostasis, rodent are 
commonly used due to better availability and accessibility of samples (blood, tissues, 
etc.) and because all mammals tend to have similar physiologic systems to preserve 
glucose homeostasis (3).  
Focusing on the hormonal aspect of BG regulation, in healthy, non-diabetic 
individuals, the pancreas produces insulin and glucagon, which are the primary regulators 
of BG. A balance between these two hormones is essential to maintain one’s BG within 
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a normal range in the fasting or post-prandial (i.e. post meal, and after the macronutrients 
have largely been absorbed and assimilated) state (4,5).  
Such balance is maintained by interactions between direct and indirect glucose regulatory 
mechanisms which involve glucose sensing cells/receptors, the endocrine system and 
the autonomic nervous system (ANS) (sympathetic and parasympathetic systems) (6). 
One situation where BG concentrations fluctuate markedly from the normal range 
is with type 1 diabetes (T1D). T1D is an autoimmune disorder in which the body attacks 
its own β-cells, thereby inhibiting the pancreas from producing insulin (7–9). Even with 
exogenous insulin therapy, in T1D, the body is unable to regulate BG levels due to the 
inability to perfectly emulate endogenous insulin secretion, in response to various 
physiological stimuli (feeding, fasting, exercise) and because individuals living with the 
disease often develop impairments in the glucagon secretion during hypoglycemia 
(typically defined as a BG ≤ 3.5 mmol/L) (10,11). In other words, even with intensive 
insulin therapy (i.e. 3-4 insulin injections per day, or with the use of a constant insulin 
infusion device, with frequent glucose monitoring), significant abnormalities in BG 
homeostasis exist, not only because insulin delivery is not perfectly normalized, but also 
because the glucose counterregulatory system appears to be lost with time (12). The 
exact biological mechanism(s) behind the loss of counterregulation is not fully known, but 
glucagon appears to be a key player in the pathophysiology of counterregulatory failure 
(9,13,14). In addition to insulin and glucagon, various neurotransmitters, and other 
hormones such as somatostatin (SST), growth hormones, glucocorticoids, and 
catecholamines (epinephrine and norepinephrine) are important players in glucose 
metabolism whose functions may be also be impacted by diabetes.  
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LITERATUR REVIEW                                                            2                                                                                                      
2.1 Overview of the pancreas 
          The pancreas is an organ with both endocrine and exocrine functional properties. 
The exocrine pancreas is composed of the acinar, centroacinar, and ductal cells that 
are responsible for production and release of variety of enzymes into the duodenum 
where they are involved in digestion (15). The endocrine pancreas makes up about 1-
2% of the entire pancreas, containing clusters of various cells, termed islets of 
Langerhans, that are responsible for the production of a number of hormones involved 
in glucose regulation and metabolism. Insulin, the hormone most widely studied, is 
produced by the beta (β) cells (16), and is released as BG levels rise to initiate glucose 
disposal into various insulin-sensitive tissues (muscle, liver, adipose), whereas 
glucagon is produced by the alpha (α) cells, and opposes the action of insulin to 
increase BG levels during hypoglycemia (1,3,15,17,18). Paradoxically, somatostatin, a 
hormone released by the delta (δ) cells, that make up ~5% of islet cells in humans, 
inhibits the release of both insulin and glucagon, although the action of this hormone on 
these other pancreatic hormones may be glucose dependent with hypoglycemia and 
hyperglycemia (high BG), respectively (1,2,16,19) (Fig.1). Additionally, a less common 
cluster of pancreatic cells, called pancreatic polypeptide (PP) cells (1-2% of pancreatic 
cells in humans), are responsible for the production of pancreatic polypeptides which 
are also involved in metabolism, albeit to a lesser extent (3,16,18,20). Epsilon (ε) cells 
are the least frequent islet cell type (<1% in humans), that produce ghrelin which is an 
appetite hormone (21).The release of these hormones is modulated by direct effects of 
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glucose and other nutrients, as well as paracrine factors released by neighboring islet 
cells, circulating hormones, and neurotransmitters released by intra-islet nerve endings.  
 
2.1.1 Pancreatic architecture: human vs. rodent models  
As mentioned earlier, pancreatic studies are commonly carried out using a rodent 
model. For scientific studies to be clinically relevant, it is essential to consider overall 
similarities and differences between a rodent and a human pancreas. Although 
pancreases from both species contain all pancreatic cell types mentioned above, there 
are differences in composition, distribution, organization, overall architecture, density, 
and size of the islet cells (22). For example, in rodents, the pancreas contains more ß-
cells (60-80% of islet cells) than in humans (50-70% of islet cells). As such, the α-cell 
composition of the pancreas in rodents tends to be lower (10-20% of islet cells) than in 
humans (20-40% of islet cells) (18,23). Moreover, organization of human islet cells 
appears to be scattered, where ~70% of ß-cells are in direct contact with non ß-cells, 
increasing the possibility of paracrine signaling involving intercellular diffusion of 
hormones (17,18,23). Unlike, in rodents, islet cells are more localized and have distinct 
patterns. In vitro studies show that α-cells are mainly concentrated around the periphery 
of the islets, ß-cells are localized in the core, and δ-cells appear to be scattered between 
the layers of α- and ß-cells (3,17,23,24). Additionally, looking at the neuronal composition 
of the two pancreases, there is less neural influences on activities of the cells of human 
islets as they are less innervated compared to that of in rodents (6). With regards to blood 
circulation, in human islets, there are no clear anatomical subdivisions between different 
cells of the islets; thus, blood flow appears to be along the layers of the cells. Unlike in 
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rodents, blood flow is from the inside of the islet with centrally located ß-cells out toward 
the periphery where the other non ß-cells reside (16,23,25). 
 
2.1.2 The endocrine pancreas: main pancreatic hormones 
               2.1.2.1 Insulin  
            Insulin is a hypoglycemic agent and an anabolic hormone that triggers storage 
of excess glucose in form of glycogen in the liver and skeletal muscle, and 
triacylglycerol in adipose tissues for later use during exercise and/or the fasted state. An 
increase in circulating insulin levels post-meal is followed by an increase in muscle- 
capillary blood flow to help increase glucose disposal into the liver, muscles, and other 
tissues, thus preventing hyperglycemia (4). Insulin also inhibits glucagon action, a 
hyperglycemic agent, resulting in inhibition of glucose production by the liver, and in turn 
maintenance of BG homeostasis (1) (Fig.1).  
Endogenous insulin is stored in secretory granules and released by the pancreatic 
β-cells. Normally, secretion rates and circulatory levels are elevated in response to a 
meal, particularly if carbohydrate is consumed, or in response to a rise in BG from any 
cause (26). A rise in BG levels is detected by glucose sensing cells present in various 
sites including the brain and the portal vein (the vein that directly delivers blood from the 
pancreas to the liver), stimulating an increase in insulin production which helps lower BG 
to normoglycemia through stimulation of glucose uptake (6,27). In the post-prandial state, 
glucose enters β-cells by means of glucose transporters (GLUT), mainly the glucose 
transporter II (GLUT-2) in humans and rodents, where its metabolism is initiated by 
glucokinases. Glucokinases phosphorylate glucose to generate glucose-6-phosphate, 
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regulating the entry of glucose into its subsequent metabolic pathways to generate ATP 
(28). A rise in intracellular ATP level inhibits activity of ATP-sensitive K+(KATP) channels, 
resulting in depolarization of β-cells. The KATP channels are normally active/open at low 
levels of BG, maintaining a negative/hyperpolarized state, whereas as rise in BG 
concentrations induces closure of KATP channels causing cell membrane potential to be 
more positive, leading to depolarization (17). Depolarization leads to influx of calcium into 
β-cells through voltage gated L-type Ca2+ channels, and in turn secretion of insulin due 
to a rise in cytoplasmic Ca2+ concentrations.  
Other than the direct regulatory effect of plasma glucose levels, intra-islet 
paracrine factors and circulating hormones also modulate insulin secretion. In an 
immunoneutralization study using an anti-glucagon antibody, insulin secretion is 
significantly stimulated under conditions of both low and high BG (29), thereby 
suggesting that glucagon has a paracrine effect to inhibit insulin secretion. Other than 
glucagon (24), SST produced by δ-cells (16,17), epinephrine (30,31), galanin (32) , 
ghrelin (18,21,33), and leptin can also inhibit insulin secretion, particularly under 
conditions of hypoglycemia (6,18,24,28,34–36).  
Several in vivo and in vitro studies (11,27,37) suggest that insulin is not released 
at a constant rate, it is rather released in an oscillatory/pulsatile manner in which a 
complex network of factors, both inside and outside of the endocrine pancreas, are 
involved in regulation of the hormone secretion (27,37). Pulsatile secretion ensures 
proper timing and amount of secretion, and likely helps to balance the release of 
pancreatic hormones through various feedback mechanisms. As a result, insulin 
production varies based on how much insulin is circulating in the blood, and how much 
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more insulin is needed to maintain BG homeostasis (27,37). In accordance with the 
pulsatile theory, insulin secretion appears to be in phase with SST, but out of phase with 
glucagon with a lag of ~ 2minutes (24). Therefore, insulin and SST levels are normally 
elevated, while glucagon levels are suppressed during hyperglycemia. Unlike, under 
conditions of hypoglycemia, insulin and SST levels tend to be lowered, while glucagon 
levels are elevated (26,34,38). The similarity between insulin and SST in secretion, and 
inhibitory effects of both on glucagon release is possibly due to the fact that β-cells and 
δ-cells share an immediate common progenitor cell (17). 
 
               2.1.2.2 Glucagon  
Glucagon is a hyperglycemic agent and a catabolic hormone. It is the primary 
counterregulatory hormone that increases BG concentration by opposing insulin’s action 
on the liver (9,13,39). Thus, unlike insulin, plasma glucagon concentration is reduced after 
a meal and increased during fasting and exercise (1,26,28). In other words, insulin and 
glucagon are secreted in an anti-synchronized fashion where glucagon production is at 
its maximum when insulin secretion is minimal (26). During exercise and/or insulin 
induced hypoglycemia, a rise in glucagon counters insulin action by stimulating glucose 
production via gluconeogenesis (i.e. de novo glucose production) and glycogenolysis (i.e. 
the breakdown of glycogen into glucose) to maintain BG levels within a normal range (~4-
7 mmol/L) (Fig.1). It is important to note that multiple mechanisms are likely to be involved 
in glucagon release, with some potential mechanisms still being examined (40). 
Glucagon secretion, at least in vitro, is modulated by a direct effect of intrinsic 
glucose sensing receptors on the α-cells (26,39,41). Like insulin, glucagon secretion is 
regulated by changes in plasma glucose levels, except that high plasma glucose levels 
		
8	
inhibits glucagon release via increased ATP production from glycolysis and the 
inactivation of various voltage gated ion channels (28,42). Under conditions of 
hyperglycemia, glucose uptake by α-cells results in elevation of cellular ATP levels that 
inactivate KATP channels, which are predominantly inhibited even in euglycemia (i.e. 
normal BG concentration). Depolarization followed by inactivation of KATP channels, result 
in closure of T-type Ca2+ and Na+ channels, reducing amplitude of action potentials which 
leads to inhibition of P/Q Ca2+ channels, and preventing Ca2+ influx, therefore glucagon 
release. In contrast, under conditions of hypoglycemia, activation of voltage gated T-type 
Ca2+ and Na+ channels result in opening of high threshold P/Q Ca2+ channels, generating 
high amplitude action potentials, and in turn glucagon release (6). It is believed that in 
healthy humans and in rodents, glucagon release during low glucose concentrations (0-
7 mmol/L)  is mainly regulated by intrinsic properties of α-cells themselves and positive 
feedback system, whereas glucagon inhibition during hyperglycemic state is mainly 
through inhibitory paracrine signaling involving pancreatic factors such as insulin and SST 
(6,39,43).  
Intra-islet circulation, defined as blood flow in the pancreas itself and between the 
pancreatic islets, appears to traverse from β cells to α- and δ-cells, according to in vivo 
studies in rodents (19,41,44) Thus, a rise in intra-islet insulin concentration acts as a 
paracrine inhibitory signal to downregulate glucagon secretion (44). Binding of both 
insulin and SST to their receptors on α-cells activates KATP  channels resulting in 
membrane hyperpolarization and closing of voltage-gated Ca2+ channels (28), thereby 
inhibiting glucagon release and reducing glucose production during hyperglycemia (26). 
An in vitro study using BG clamping techniques in an isolated human pancreas shows 
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that there is a significant inhibition of glucagon secretion during low-glucose exposure 
(perfusion), but significant stimulation of glucagon secretion during high-glucose 
perfusion (29). These results indicate the existence of regulatory feedback loop between 
α- and β-cells where insulin promotes either a rise or a reduction in glucagon release 
during hypoglycemia and hyperglycemia, respectively. Consequently, insulin appears to 
have a glucose-dependent regulatory role in the secretion of glucagon.  
Other than SST (17,39,43) and insulin, other paracrine inhibitors of glucagon 
include co-secreted factors from β-cells such as  Zn2+ ions,  γ-aminobutyric acid (GABA) 
(35,45) and γ-hydroxybutyric acid (GHB) (46), both of which are also inhibitory 
neurotransmitters produced in the brain (6,16,35,37). On the other hand, The autonomic 
nervous system and in particular the stimulatory effects of epinephrine produced by the 
adrenal medulla increase glucagon secretion (6,47).  
 
              2.1.2.3 Somatostatin  
Somatostatin (SST), a polypeptide with a very short half-life (30 seconds to 1 
minute) in circulation, was originally isolated from the hypothalamus, and exists in two 
main forms, SST14 and SST28, which are made up of 14 and 28 amino acids, 
respectively (17,24). Both forms are derived from the precursor pre-prosomatostatin, 
cleaved into pro-somatostatin, which undergoes translational modifications to produce 
SST14 and 28 (17). Although both forms are produced in the hypothalamus, neuronal 
cells of the central nervous system (CNS), gastrointestinal (GI) tract (43,48), and the 
pancreas (18,43,48), SST28 is mainly produced in the GI tract; whereas SST14 (5-10% 
of circulating SST) is predominantly produced by the δ-cells of the pancreas (17). SST is 
an inhibitory regulator of various systems throughout the body (7,49), and acts as a 
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neurotransmitter in the CNS  (8,17,43). SST is a major inhibitor of growth hormone (GH) 
secretion in the pituitary (50) , and as mentioned above, is a paracrine inhibitor of insulin 
and glucagon under conditions of hypo- and hyperglycemia, respectively (49) (Fig.1). SST 
can also alter secretion of α- and β-cells indirectly by means of various proteins, enzymes, 
and hormones such as epinephrine and cortisol (25). 
In the pancreas, SST14 and SST28 are produced and stored by the δ-cells, and 
have inhibitory effects on biochemical pathways, specifically targeting glucose regulation 
(7,49). It appears that SST14 is more common in terms of its inhibitory effects on glucagon 
secretion, whereas SST28 is more potent in the inhibition of insulin (51). In rodents, α-
cells are generally more sensitive to the inhibitory effects of SST than β-cells (6,49), which 
could possibly be due to closer spatial association between δ-cells and α-cells, which 
creates a more direct cell-cell contact (6). It is important to note that it is not yet fully 
known if pancreatic SST exerts whole-body effects. This is because pancreatectomy 
(pancreas removal) has no impact on circulating levels of SST, likely because most 
circulating SST is derived from the intestines (17). 
Just like insulin and glucagon, SST is produced in a pulsatile fashion with its 
secretion in phase with insulin, but asynchronous to glucagon (24,52). The fact that SST 
release is out of phase with glucagon suggests that the hormone has a stronger inhibitory 
effect on glucagon secretion rather than insulin secretion. An in vitro study using anti-SST 
antibody to neutralize endogenous SST in human pancreata, shows an increase in insulin 
release in the presence of the antibody, and under conditions of both low and high glucose 
infusions, suggesting inhibitory role of SST in insulin secretion. Surprisingly, inhibition of 
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SST tends to increase glucagon secretion, but under low glucose infusion only, 
suggesting limited/tonic inhibitory effects of SST on glucagon production (29).  
Another in vitro study used a SST knockout model (sst-/-) to look at stimulus-
induced insulin and glucagon levels in the absence of neuronal, gastrointestinal, and/or 
pancreatic sources of SST. Results show significant differences in hormonal levels with 
both insulin and glucagon being lower in the presence of pancreatic SST specifically (49). 
Also, administration of exogenous SST is shown to inhibit both glucagon and insulin 
(26,29,53,54). A study in male Sprague-Dawley (SD) rats shows, following a rise in BG 
levels, SST is initially and very briefly suppressed, causing a simultaneous increase in 
both insulin and glucagon. Then, after ~2 minutes, SST along with insulin rise 
exponentially to reduce glucagon release, preventing hyperglycemia (24)(Fig.1). 
Consequently, it is evident that SST regulates secretion of both hormones with a profound 
impact in the presence of a stimulus like glucose.  
Pancreatic SST production itself is regulated by different factors. Similar to α- and 
β-cells, SST producing δ-cells use glucose sensing mechanisms to detect changes in BG 
levels (34). Direct stimulatory impact of glucose on hormone secretion is observed when 
specific glucose transporters on δ-cells, GLUT-1 and GLUT-3, facilitate the uptake of 
glucose into the cells where it is metabolized to produce ATP, increasing the ATP to ADP 
ratio. Like β-cells, a rise in intracellular ATP levels alters the activity/status of KATP 
channels. More specifically, a rise in extracellular BG levels elevates ATP production and 
closes/inactivates KATP channels, thereby initiating membrane depolarization causing an 
influx of Ca2+ through voltage gated Ca2+ channels, which in turn increases SST secretion 
(17). Paracrine factors such as glucagon and glutamate (an excitatory factor co-released 
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with glucagon) (16,19,25,42), various amino acids such leucine and arginine, GABA, and 
Urocrtin 3 which is a peptide co-released with insulin from β-cells (17,55), all stimulate 
SST release. The role of insulin itself in regulation of SST is not fully understood yet. 
Some studies suggest that insulin has both stimulatory and inhibitory effects of on SST 
secretion (17).  
Both SST14 and SST28 bind to five different somatostatin receptor (SSTR) 
subtypes of inhibitory G-protein coupled receptors (i.e. SSTR1-5) expressed on various 
organs, such as the pancreas, brain, liver, intestines, stomach, and the kidneys targeting 
various biological pathways (43,48,51,56). Activities of SST receptors are modulated by 
voltage gated K+ and Ca2+ channels, a variety of substrates, and receptors endocytosis 
and trafficking (53). SST binding to its receptors on α-and β-cells suppresses the electrical 
activity and exocytosis of glucagon and insulin granules, respectively (17). In rodents, 
somatostatin receptor type II (SSTR2) is specifically expressed in glucagon producing α-
cells whereas somatostatin receptor type V (SSTR5) is mainly expressed in insulin 
producing β-cells (48,53,54,57–59). Therefore, SST binding to SSTR2, and SSTR5 
inhibits glucagon and insulin secretion, respectively. Pancreatic β-cells in humans 
express all five receptors subtypes with type I being the most predominant type, followed 
by type V which is expressed by about 87% of β-cells, and type II expressed by 47% of 
β-cells, while type III and IV are poorly expressed (53). In humans, unlike in rodents, 
SSTR2 appears to be a major SST receptor subtype expressed in both α and β-cells (53). 
Interestingly, perfusion of isolated human pancreases with SSTR2 agonist show 
significant reduction in insulin levels under conditions of both hypo- and hyperglycemia, 
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highlighting the role SST and SSTR2 in insulin regulation in humans (25,53,57). If these 
and other mechanisms exist in vivo are unclear.  
 
2.2 Other (pancreatic and non-pancreatic) blood glucose regulatory hormones 
Glucocorticoids (i.e. cortisol also known as corticosterone in rodents), GH, and 
catecholamines (i.e. epinephrine and norepinephrine) are all involved in modulating 
glucose metabolism, either directly, or by regulating the release of other hormones such 
as glucagon (60). For example, hypoglycemia leads to a rise in circulating cortisol and 
epinephrine resulting in inhibition of insulin and SST secretion (17), a reduction in hepatic 
and peripheral insulin sensitivity, and in turn reduced glucose uptake in the muscles and 
other tissues in an effort to increase BG levels back to euglycemia (61). Epinephrine 
binding to its receptors on α-cells causes cellular depolarization (28), an influx of Ca2+ 
through opening of Ca2+ channels and a stimulation of glucagon release (6). The increase 
in circulating glucagon facilitates renal and hepatic glucose production/mobilization during 
hypoglycemia (30,61,62). Interestingly, one study suggests that epinephrine’s stimulatory 
effects on glucagon release may be weak or absent in humans (28). 
Ghrelin is a metabolic hormone that is mainly produced in the GI tract but is also produced 
by the ε-cells of the pancreas, hypothalamus, kidneys, and pituitary glands (63). Ghrelin 
regulates food intake, body weight, and the release of GH, insulin, glucagon, SST and 
pancreatic polypeptide (18,19,33,50). In both humans and rodents, a rise in ghrelin levels 
during the fasted state inhibits Ca2+ mediated insulin release, and stimulates food intake 
(Fig2). Therefore, ghrelin appears to aid with counterregulatory responses to 
hypoglycemia through reduction of circulating insulin levels and by increasing the drive 
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for feeding (18,50,63). However, ghrelin is normally inhibited under conditions of insulin 
induced hypoglycemia, or hyperinsulinemia; therefore, it is not an adequate 
counterregulatory agent by itself (64). Leptin is a lipid-derived appetite hormone that 
regulates plasma glucose levels independent of actions on food intake and energy 
expenditure.  Leptin directly contributes to BG homeostasis through its actions as an 
inhibitory regulator of both insulin and glucagon, and a modulator of glucose uptake in the 
peripheral tissues (65). Galanin, a neuropeptide with multiple physiological activities 
including metabolism, is released from intrapancreatic nerve endings, and inhibits insulin 
secretion, facilitating recovery from hypoglycemia (32). Pancreatic polypeptide, a 
hormone produced by the PP cells (or F cells) of the pancreas, is involved in regulation 
of satiety and metabolism as well. PP production is regulated through neuronal signals, 
mainly cholinergic factors, and arginine levels (20,46). Like insulin, PP levels rise after 
food intake, inhibiting glucagon production under conditions of high BG levels (18,46). 
GABA, a factor co-released with SST from δ-cells, stimulates SST secretion, thereby 
regulating insulin and glucagon secretion through feedback mechanisms (28). Incretin 
hormones are hypoglycemic agents that stimulate insulin release but inhibit glucagon 
secretion in response to meals. The two most widely studied incretins are glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is 
made in the endocrine cells of small intestine and colon, while GIP is made by cells in the 
upper small intestine, both regulating appetite and food intake. A rise in GLP-1 and/or 
GIP levels result in enhancement of insulin and SST secretion, suppression of glucagon, 
and inhibition of gastric emptying, thus contributing to maintenance of BG homeostasis 
(17,66,67). 
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Figure 1. The role of pancreatic hormones in blood glucose regulation Insulin 
produced by the β-cells, glucagon produced by the 𝛼-cells, and somatostatin produced 
by the δ-cells are the main pancreatic hormones. Insulin functions to lower blood 
glucose levels during hyperglycemia, whereas glucagon counters the action of insulin 
to increase blood glucose levels during hypoglycemia. Somatostatin is an inhibitory 
regulator of both. A balance between these hormones is required for maintenance of 
blood glucose homeostasis. Inset: Insulin, glucagon, and somatostatin secretion 
during various blood glucose levels (Adapted from Rorsman and Huising, 2018).  
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2.3 The liver’s role in blood glucose homeostasis 
The liver is a major metabolic organ, that regulates energy metabolism through 
interactions with skeletal muscle, the GI tract, adipose tissue, and the brain. In the post-
prandial state, excess plasma glucose enters the liver via the portal vein to be stored in 
form of glycogen, the main form of carbohydrate storage in mammals, for later use (68). 
The portal vein not only carries nutrients and hormones from the pancreas to the liver; it 
also contains neurons and glucose sensors (64) that are sensitive to changes in plasma 
glucose levels. Deviations from euglycemia, and the rate at which BG levels fluctuate, 
result in appropriate responses involving activation and firing of glucose sensors in the 
portal vein. Activation of glucose sensors results in functional modifications of tissues 
such as the liver, hypothalamus, brain, and the endocrine pancreas to maintain BG 
homeostasis through regulation of food intake and hepatic glucose uptake (64). Liver 
glycogen concentrations are controlled by many factors, but mainly the rate of portal vein 
delivery of glucose to the liver and portal vein insulin levels (62,69). Both high glucose 
and insulin levels in the portal blood after food intake normally reduce glucose production 
and stimulate glycogen synthesis by the liver (69). It is important to note that BG levels 
are normally higher in the portal vein than in peripheral circulation. This creates a 
concentration gradient from the liver to peripheral tissues, facilitating glucose delivery to 
peripheral tissues. Pancreatic hormones (i.e. insulin and glucagon) are also released into 
the portal vein, extracted by the liver, and later delivered into the peripheral circulation. 
The relative concentrations of insulin and glucagon, as the main BG regulatory hormones, 
help determine whether the liver functions as an organ of fuel storage or fuel production 
(23).  
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The liver is the main organ of glucose production through glycogenolysis and 
gluconeogenesis when BG levels drop below the normal range, and muscle glycogen 
stores are low after exercise (1,38). Hormonal and neuronal signals, plus availability of 
nutrients dictate which source of energy is dominating at a given time (69). 
Glycogenolysis is the main source of endogenous glucose production (EGP) during early 
stages of fasting and/or hypoglycemia, whereas gluconeogenesis is the predominant 
method of glucose production during prolonged fasting and/or hypoglycemia. When 
hepatic glycogen levels are low, the liver produces glucose in a de novo fashion using 
pyruvate, glycerol, and amino acids as precursors (62,69). Glucagon and epinephrine are 
two major counterregulatory hormones that stimulate glycogenolysis and 
gluconeogenesis (62). Other hormones such as growth hormone, and glucocorticoids 
also employ various pathways and mechanisms to induce glycogen break down and/or 
gluconeogenesis to increase circulating glucose levels in the fasted state and during 
exercise (69)  
 
2.4 Skeletal muscle and blood glucose regulation 
Skeletal muscle is the main target for insulin-induced glucose uptake, and the 
most important tissue in limiting glucose uptake during counterregulatory responses to 
hypoglycemia (68). During conditions of hyper- and hypoglycemia, insulin-induced 
glucose uptake in skeletal muscles increases and decreases, respectively, to maintain 
BG homeostasis, and spare glucose for the brain.  In humans, most glycogen (~500 g in 
total in the average adult male) is stored in skeletal muscle, and can be used during 
high intensity exercise (68). However, hepatic glycogen remains the main source for 
EGP via glycogenolysis and is essential for maintenance of whole-body BG 
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homeostasis. Glycogen breakdown in skeletal muscle can only provide energy locally 
during exercise, as the glucose doesn’t enter the systemic circulation. Lactate, an 
alternative fuel for glucose and a byproduct of muscle glycogen breakdown, can be 
transported to the liver where it is used a major substrate required for gluconeogenesis 
during hypoglycemia (30,68).   
In accordance with their metabolic and mechanical properties, age, sex, and 
species, skeletal muscles are composed of different muscle fibers, or basically a 
combination of them (70). Diversity in fiber type and muscle function is due to presence 
of different myosin isoforms (71). Glycolytic and oxidative are the two main fiber types. 
Glycolytic fibers (Type IIb fibers) are fast twitch, fatigue rapidly, have very low 
mitochondria content and rely on glucose as the main source of energy. Fast twitch 
oxidative (Type IIa) fibers are moderately resistance to fatigue, and use glucose as the 
main source of ATP production. In contrast, slow twitch (Type I) fibers, have high 
mitochondrial content, and use oxidative phosphorylation as the main method of ATP 
synthesis (70,72,73).  
In rodents, just like with other mammals, skeletal muscles have different fiber 
composition based on metabolic and contractile function. For example, in lower limb, 
tibialis anterior and gastrocnemius are composed of a mixture of type IIa and IIb fibers 
(70,73), extensor digitorum longus  and plantaris are mainly made of type IIb fibers  
(71,74) whereas soleus predominantly contains type I (71,74). 
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2.5 Glucose regulation in type I diabetes  
Due to absence of endogenous insulin, chronic and intensive insulin treatment is 
required to manage BG levels in individuals with T1D. Poorly controlled glycaemia is 
associated with major complications such as renal failure, cardiovascular diseases, 
neuropathy, blindness, amputations, and stroke (75). However, even intensive insulin 
use has some negative side effects, the most catastrophic being severe hypoglycemia 
(loss of consciousness, possibly convulsions and death). Excessive insulin 
administration over years in diabetes appears to cause significantly dysregulated 
glucagon secretion during hypoglycemia in insulin-treated diabetes (11,26,34,76). 
Additionally, blunted epinephrine and cortisol responses due to maladaptation in the 
central and peripheral nervous systems, that result in delayed response activation (i.e. 
higher activation threshold), and reduced magnitude (14). All of these factors contribute 
to defective counterregulatory responses to hypoglycemia and/or recurrent 
hypoglycemia, which worsens with time and/or age (76,77). 
Glucagon is known to play a key role in the pathophysiology of attenuated 
counter-regulation as it is the first line of defense against hypoglycemia in healthy 
individuals (61). Under the healthy conditions, when BG levels fall below 4.4 mmol/L 
(75), counterregulatory responses including a rise in glucagon and a reduction in insulin 
secretion, increase glucose production, and decrease insulin-induced glucose uptake in 
peripheral tissues, mainly in skeletal muscle, to maintain whole body BG homeostasis. 
In T1D, as plasma glucose levels drop, there is an attenuation in glucagon secretion 
along with impaired autonomic and adrenomedullary (reduced catecholamine) 
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responses all of which result in increased depth and duration of hypoglycemia 
(10,26,35). 
Although glucagon counterregulation involves multiple pathways and factors, 
some studies suggest that the insulin “switch-off” by the ß-cells is the most important 
stimulus for glucagon secretion; thus, activation of glucagon counterregulatory 
responses (26). The switch-off theory involves intra-pancreatic interactions between 
different islet cells, deemed essential for glycemic homeostasis, and a normal 
counterregulatory system. It is defined as downregulation/termination of intra-pancreatic 
factors such as insulin and SST, that exert inhibitory effects on glucagon secretion 
during low BG (6,26).Therefore, absence of endogenous insulin in T1D, and in turn the 
loss in switch-off by the ß-cells when BG falls, is thought to contribute to the defective 
glucagon counterregulation observed in patients living with T1D (11,26,34,38,76). In 
support of the switch-off theory, a rodent study in which insulin was infused into the 
pancreas, but was not turned off during hypoglycemia, shows suppression of glucagon 
counterregulatory responses (38). 
Other rodent studies of T1D (11,26,76) suggest that, chronic insulin use results in 
high basal glucagon levels (hyperglucagonemia), possibly due to absence of intra-islet 
insulin, therefore lack of post-prandial glucagon suppression. The lack of initial rise in 
insulin levels, after a meal intake, as an inhibitory signal for glucagon production, leads 
to continuation of glucagon production even though BG levels are still rising (11,23). 
This failure of glucagon to drop with a meal in T1D likely contributes to post-prandial 
hyperglycemia. This increase in basal intra-islet glucagon release after meals reduces 
the difference between basal and peak levels (i.e. during hypoglycemia and/or fasting), 
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thus lowering the amplitude of glucagon secretory pulses (11). In other words, the 
higher basal glucagon levels are, the less efficient glucagon responses would be during 
hypoglycemia. Consequently, some investigators have proposed that a reduction in 
basal glucagon levels in diabetes might lead to a significant improvement in glucagon 
responsiveness to hypoglycemia (11,26). Indeed, therapeutic agents such as leptin and 
GLP-1 that inhibit glucagon production may improve glucagon counterregulation during 
hypoglycemia, even in absence of insulin signaling (11,78,79). Interestingly, the 
administration of exogenous SST in patients with hyperglucagonemia tends to improve 
glycemic management and lower exogenous insulin needs (17). 
In addition to altered glucagon secretion in diabetes (i.e. elevated levels post 
meal and blunted release during hypoglycemia), animal and human studies suggest 
negative alterations in glycogen synthesis and metabolism in T1D that appear to be 
aggravated by insulin management. Poorly managed TID results in reduced glycogen 
production and breakdown, likely because of low insulin and high glucagon post 
feeding, which may contribute to insufficient EGP and defective counterregulatory 
responses during hypoglycemia (62). Even with insulin therapy, the lack of hepatic 
glycogen breakdown during hypoglycemia in subjects with T1D persists, and it is likely 
due to a significantly lower concentration of basal, or fasting hepatic glycogen content 
even after insulinization (62,69). Lack of change in hepatic glycogen content in the T1D 
subjects during hypoglycemia suggests that gluconeogenesis (not glycogenolysis) is the 
predominant source of EGP when BG levels fall (62). Thus, it is likely that the 
underlying mechanisms that impair EGP during hypoglycemia include a failure in the 
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drop in portal insulin levels, a blunted glucagon response, impaired catecholamine 
release and a low level of liver glycogen content (62,69). 
Taking into consideration what is discussed above, a combination of chronic 
insulin use, disruption of islet architecture and intra-islet cross-talk (i.e. absence of 
intraislet insulin which is the stimulatory signal for activation of α-cells during 
hypoglycemia) (26,35,76),  glucose blindness of α-cells (i.e.inability to detect changes in 
glucose levels), autonomic neuropathy (desensitized autonomic responses), and 
alteration in glycogen metabolism may explain why people living with T1D often develop 
a loss of glucagon conterregulation over time (13,35,38,75). 
 
2.6 Hypoglycemia 
To avoid long-term health complications associated with sustained elevations in 
glycaemia (i.e. heart disease, kidney failure, nerve damage, vision impairments and 
blindness), control of high BG concentrations with insulin is a primary clinical objective for 
T1D. However, with intensive insulin therapy, impaired counterregulatory responses, and 
with exercise, the risk for hypoglycemia increases markedly (77,80,81). Hypoglycemia 
can lead to physical and/or psychosocial impairments, neuroglycopenia, cognitive 
dysfunction, and if left untreated can lead to brain damage, seizures, and in severe cases, 
death. About 4-10% of deaths in T1D has been associated with hypoglycemia 
(17,74,79,81). On the other hand, chronic hyperglycemia can cause toxicity leading to β-
cell dysfunction and a host of other co-morbidities (1). If one could better titrate insulin 
dosage upward, without causing hypoglycemia, T1D treatment and glycemic 
management would dramatically improve, reducing occurrences of associated 
complications.  
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As mentioned earlier, a defective counterregulatory mechanism is associated with 
hypoglycemia. Studies show that, defects in glucagon counterregulation is associated 
with at least a 25-fold increased risk of severe hypoglycemia in T1D (10,30,80), in part 
due to inadequate glucagon counterregulation (38,61,80,82). Moreover, antecedent 
insulin induced, and/or exercise induced, hypoglycemia plays a major role in impaired 
glucagon counterregulation in T1D, thus increasing the chances of future hypoglycemic 
episodes (75,81,83,84). It is important to note that hyperglycemia itself inhibits glucagon, 
but hypoglycemia on its own is not sufficient for an adequate glucagon counterregulatory 
response. Therefore, other regulatory factors are involved in providing protection against 
hypoglycemia (26). 
In healthy individuals, the neuroendocrine system provides protection against 
hypoglycemia. Detection of low BG in the brain, stimulates the activation both 
autonomic and endocrine responses to downregulate insulin secretion and increases 
hormones that counter insulin when BG levels drop (i.e. glucagon, catecholamines, GH, 
and cortisol) (11). The brain is the main site for detection of hypoglycemia (64). In 
rodents, the ventromedial hypothalamus (VMH) appears to be the main trigger site for 
counterregulatory responses such as glucagon and epinephrine. GABA is an inhibitory 
neurotransmitter that acts within the VMH to modulate the magnitude of both the 
glucagon and epinephrine responses to hypoglycemia in nondiabetic rats (35,85). Both 
human and rodent studies suggest that, GABA functions to downregulate glucagon 
counterregulatory responses to hypoglycemia (35). Studies using two different animal 
models of T1D, the Biobreeding (BBD; a diabetic rat model that simultaneously 
develops T1D) and Streptozotocin (STZ) rodent models, show that basal GABA levels 
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in the VMH are abnormally high in T1D. Observations indicate that in response to an 
insulin-induced hypoglycemic challenge, VMH GABA levels decrease in control animals 
which corresponds with activation of both the glucagon and epinephrine responses. In 
contrast, VMH GABA levels remain elevated during hypoglycemia in both diabetic 
models, and this phenomenon is associated with absent glucagon and attenuated 
epinephrine responses (35,85). Therefore, elevated levels of GABA in VMH in T1D may 
be an important contributor to counterregulatory failure in diabetic rats exposed to 
hypoglycemia.   
In addition, activation of sympathetic system generates responses to 
hypoglycemia that result in hypoglycemia awareness which is associated with signs and 
symptoms such as sweating, dizziness, hunger, lack of concentration, anxiety, and 
nausea (75). Hypoglycemia awareness gives the patient the opportunity to take 
appropriate actions necessary for recovery from hypoglycemia before it becomes life 
threatening. Research suggests that responses to hypoglycemia depend on the rate of 
fall in BG with higher sympathoadrenergic responses during a slower fall in comparison 
with a rapid fall (64). However, such lifesaving mechanisms are impaired in individuals 
living with T1D. In addition to causing hormonal imbalances, hypoglycemia can cause 
defects in sympathetic and adrenergic responses making it more difficult for detection by 
the patient; therefore contributing to hypoglycemia unawareness, also knowns as 
hypoglycemia associated autonomic failure (HAAF) (75,81,85). Inability to detect early 
warning signs and symptoms of hypoglycemia over time can result in a reduction in 
magnitude and intensity of sympathetic, adrenal, and glucagon counterregulatory 
responses, which then are only generated at a significantly lower BG, putting diabetic 
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patients in danger of severe and/or recurrent, or simply repeated, hypoglycemia 
(14,75,81,83). One rodent study suggests that repeated hypoglycemia causes structural 
changes in glucose sensing regions of the brain, thus significantly increasing likelihood 
of future episodes (77). Additionally, upregulation of glucose metabolism in the brain 
through increased expression of glucose transporters, and in turn glucose uptake as a 
result of cellular adaptation to repeated hypoglycemia, can ultimately shut down 
sympathoadrenal responses. In short, downregulation of neuronal and hormonal 
responses with recurrent hypoglycemia leads to hypoglycemia unawareness (75,77). 
Patients with T1D, on average, experience 1-3 episodes of severe hypoglycemia per 
year, and hypoglycemia unawareness increases incidence of severe hypoglycemia by 6-
fold (75,77). The risk increases over time with duration of diabetes, and intensity of insulin 
therapy for strict glycemic control. Therefore, the fear of hypoglycemia appears to be the 
limiting factor in glycemic management of diabetes (39,77,80). Antagonism of autonomic 
responses to hypoglycemia such as epinephrine by itself does not impair 
counterregulatory response suggesting pancreatic regulation of BG plays a major role in 
glycemic control and hypoglycemia prevention (10). An in vitro study of denervated non-
diabetic human pancreas (86) shows a reduction and an increase in intra-islet insulin and 
glucagon, respectively, in response to hypoglycemia. Unlike, in presence of an intact 
autonomic system, but an impaired pancreatic counterregulatory system, recovery from 
hypoglycemia becomes a challenge.  
In summary, decreased hormonal counterregulation makes future episodes of 
hypoglycemia not only more likely, but also more severe due to decreased 
sympathoadrenal responses and reduced hypoglycemia awareness (35,75,81,85). 
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Although the role of recurrent hypoglycemia in counterregulatory impairments is 
reasonably well established, the underlying mechanisms are not fully understood. It is not 
known whether it is the hyperinsulinemia induced hypoglycemia itself and/or the exposure 
to associated factors that leads to the development of impaired glucose counterregulation 
(83). 
 
2.7 Somatostatin receptor type II antagonist (SSTR2a) 
The over-production of SST in diabetes may be one factor contributing to a blunted 
glucagon response to hypoglycemia. In both healthy, nondiabetic humans and animals, 
where β-cells are intact, SST may have minimal inhibitory effects on glucagon producing 
α-cells because of its dominant role in β-cell (insulin) inhibition, whereas in T1D, SST 
paracrine inhibition of α-cells rises due to absence of β-cells (7,80,82). In addition to 
absence of β-cells in T1D, the number of δ-cells, plasma SST, pancreatic pro-
somatostatin mRNA, and SST protein levels are also increased causing increased 
suppression of glucagon producing α-cells, and a reduced counterregulatory response 
under conditions of hypoglycemia (8,43,49,58).  
Since elevated SST levels in diabetes leads to increased inhibition of glucagon 
responses under conditions of hypoglycemia, researchers have shown that a 
somatostatin receptor type 2 antagonist (SSTR2a) can improve glucagon 
counterregulatory responses to low BG levels (7–9,17) (Fig.2). In a series of in vivo 
experiments on rodents, it was shown that that a newly developed compound, PRL-2903 
which is a SSTR2a, results in an improved glucagon response to hypoglycemia induced 
by insulin administration or by exercise (7–9,87). Additionally, a SSTR2 knockout model 
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in mice has shown a two-fold increase in glucagon secretion (58,88). Although SSTR2a 
is shown to improve the blunted glucagon response during 
hyperinsulinemia/hypoglycemia in T1D, the pathophysiology behind this effect is not fully 
understood.   
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Figure 2. The role of somatostatin in hypoglycemia development and effects of 
SSTR2a on hypoglycemia prevention. Somatostatin (SST) is a major paracrine 
inhibitory regulator of glucagon secretion. Therefore, abnormal inhibition of glucagon 
secretion by STT can impair counterregulatory responses to low blood glucose which 
leads to hypoglycemia development. As somatostatin receptor type II is mainly 
expressed on 𝛼-cells, a somatostatin receptor type II antagonist (SSTR2a) may improve 
glucagon counterregulatory responses to hypoglycemia by blocking inhibitory effects of 
SST on glucagon secretion.  
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2.8 Summary 
In summary, BG regulation and homeostasis requires a complex network of 
biochemical pathways involving a variety of biological factors including nutrients like 
glucose, hormones such as insulin and glucagon, and neurotransmitters like GABA. In 
non-diabetic individuals, the pancreas produces three major BG regulatory hormones, 
insulin, glucagon, and SST secreted by α-, ß-, and δ-cells, respectively. Insulin and 
glucagon are the primary regulators of BG where insulin functions to lower BG levels, and 
glucagon opposes the action of insulin by increasing BG levels. A balance between these 
hormones is essential to maintain one’s BG within a normal range at all times. SST is an 
inhibitory regulator of both insulin and glucagon under conditions of hypo- and 
hyperglycemia, respectively. Secretion of these hormones is directly affected by glucose 
and other nutrients, as well as paracrine and autocrine mechanisms (Fig.3). Defects in 
production, secretion, and/or functions of one or some of these hormones and factors 
lead to loss of BG homeostasis in T1D. Unfortunately, with T1D, the body is unable to 
regulate BG levels due to the loss of endogenous insulin, and impairments in the insulin-
glucagon dynamic, which leads to the loss of BG counterregulation. A defective 
counterregulatory system is associated with a dangerous, life-threatening, low circulating 
glucose condition called hypoglycemia, and glucagon appears to be a key player in the 
pathophysiology of this condition. Glucagon prevents hypoglycemia; however, a defective 
glucagon counterregulatory system, and recurrent hypoglycemia attenuates 
counterregulatory responses to a greater extent, increasing vulnerability to subsequent 
bouts of hypoglycemia. As SST normally inhibits glucagon secretion and its levels are 
upregulated in T1D, a somatostatin receptor type II antagonist (SSTR2a), PRL-2903, may 
improve glucagon responses attenuated by recurrent hypoglycemia.   
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Figure 2. Summary: Regulation of pancreatic hormones involves complex 
intrasilet interactions. Regulation of blood glucose regulatory hormones involves 
both intracellular and extracellular factors. A complex instraislet communication 
network incorporating feedback mechanisms and paracrine signaling ensures 
hormonal balance and maintenance of blood glucose homeostasis in the healthy state.  
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RATIONALE AND OBJECTIVE                                         3 
3.1 Rationale 
T1D is a metabolic disorder in which defects in both insulin and glucagon 
production/secretion play a role. Chronic use of exogenous insulin while life sustaining 
in T1D, combined with a defective counterregulatory system, creates a serious 
complication called hypoglycemia. Although the role of recurrent hypoglycemia, or 
simply repeated hypoglycemic episodes, in counterregulatory impairments is reasonably 
well established, the underlying mechanisms are not fully understood. It is not known if 
it is the hyperinsulinemia induced hypoglycemia itself and/or the exposure to associated 
factors that leads to the development of impaired glucose counterregulation that is 
behind the high rates of the complication in this disease state (83). SST production by 
the δ-cells of the pancreas exerts inhibitory effects on glucagon secretion, and elevated 
SST levels in T1D likely cause a greater suppression of glucagon producing α-cells 
under conditions of hypoglycemia (7–9,17,43,58,80). Since SST is known to inhibit 
glucagon, a somatostatin receptor type II antagonists (SSTR2a) may be able to restore 
the dysregulated glucagon counterregulation during hypoglycemia as the somatostatin 
receptor type II is specifically expressed in glucagon producing α-cell (7–9,17,53,58). In 
a series of in vivo experiments on rodents, it was shown that that a newly developed 
compound PRL-2903, which is a highly selective SSTR2a, results in an improved  
glucagon response to hypoglycemia induced by insulin administration or exercise (7–
9,87). Additionally, a SSTR2 knockout model in mice has shown a two-fold increase in 
glucagon secretion at euglycemia (58,88).  
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Therefore, SSTR2a could be a novel therapeutic agent which would be used in form of 
combination therapy with insulin, enabling better glycemic control with intensive insulin 
therapy without the fear of hypoglycemia. 
Although SSTR2a is shown to improve the blunted glucagon response during 
hyperinsulinemia/hypoglycemia in T1D, the pathophysiology behind this effect is not 
fully understood. It is unclear whether the effectiveness of SSTR2a is dependent on 
diabetes, or diabetes related factors (i.e. elevated SST levels), or because of 
antecedent hypoglycemia, the latter of which can occur in non-diabetic organisms. In 
other words, we do not know if the SSTR2a would be able to improve impaired 
glucagon responses to hypoglycemia in absence of diabetes. Therefore, in this thesis, 
we designed a nondiabetic rodent model, instead of a diabetic model, that mimics the 
counterregulatory failure in T1D. Our goal was to eliminate the diabetes-related 
variables, except for recurrent hypoglycemia, to better understand the functional 
properties of the antagonist. 
3.2 Objectives 
The objectives of this study were to develop a rodent model of recurrent 
hypoglycemia that rapidly develops a weakened glucagon counterregulatory response 
to hypoglycemia, and determine if a SSTR2a would be able to improve glucagon 
counterregulation in this model. In this study, we specifically examined the effects of 
PRL-2903, a SSTR2a, on glucagon and insulin secretion during hypoglycemia, in our 
newly established rodent model of recurrent hypoglycemia that mimics 
counterregulatory failure in T1D. The primary goal of this study was to determine the 
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impact of the antagonist on circulating insulin and glucagon levels, and in turn glucose 
production via glycogenolysis in such abnormal (compromised counterregulatory 
system) condition.  
3.3 Hypotheses 
We hypothesized that the antagonism of SSTR2 on α-cells relieves the inhibitory 
effects of SST on glucagon secretion thereby improving the compromised glucagon 
response. Since in our non-diabetic model β-cells are still intact, endogenous insulin 
secretion exists, but we expect no significant impact on insulin release in presence of 
the SSTR2a, as the antagonist used, PRL-2903, is specific for the type II receptor which 
is mainly expressed on the α-cells in rodents. We also anticipated that hepatic, but not 
skeletal muscle glycogen content may be lower in the SSTR2a group compared to 
controls animals because improved glucagon responses in the treatment group leads to 
increased glycogenolysis, and in turn glucose production in an attempt to recover from 
hypoglycemia.     
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Introduction  
Blood glucose (BG) regulation relies on an interconnected network of multiple 
organs and biochemical pathways. Both the central (hypothalamic) and peripheral 
(hormonal) counterregulatory pathways operate in a synchronized manner to maintain 
BG levels within a normal range (i.e. 4.0-7.0 mmol/L) during exercise, fasting, and feeding 
states (1,2). Focusing on the hormonal aspect of BG regulation, in healthy, non-diabetic 
individuals, the pancreas produces the opposing hormones, insulin and glucagon, which 
are the primary regulators of BG. Insulin functions to lower BG levels, whereas glucagon 
counters the action of insulin by elevating BG concentrations. A balance between these 
two hormones is essential to maintain one’s BG concentration within a normal range in 
the fasted or post-prandial states (~4-7 mmol/L) (4,5). One situation where BG levels 
fluctuate markedly from the normal range is with type 1 diabetes (T1D). T1D is an 
autoimmune disorder in which the body attacks its own β-cells, thereby preventing the 
pancreas from producing insulin (7–9,77). Because of this loss, patients with T1D have 
difficulty regulating their BG levels. To avoid long-term health complications associated 
with sustained elevations in glycaemia (i.e. heart disease, kidney failure, nerve damage 
and eye disease), tight control of glucose remains the primary clinical objective for 
patients living with T1D. However, even with intensive insulin therapy via multiple daily 
insulin injections or by continuous subcutaneous insulin infusion devices (i.e. insulin 
pumps), significant abnormalities in BG homeostasis exist, not only because insulin 
delivery is not perfectly normalized, but because the glucose counterregulatory system is 
also impaired to some degree. Specifically, prolonged diabetes is associated with loss of 
glucagon secretion and imbalances in the insulin-to-glucagon dynamic, and loss of 
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glucose counterregulation when blood glucose levels drop below a normal range (i.e. <3.9 
mmol/L). The exact biological mechanism(s) behind the loss of counterregulation is not 
fully known, but glucagon appears to be a key player in the pathophysiology of 
counterregulatory failure (9,13,14,26). Possible explanations as to why people living with 
T1D often develop a loss of glucagon counterregulation over time include chronic insulin 
use, disruption of islet architecture, absence of intra-islet insulin (11,26,35,76), glucose 
blindness of α-cells, blunted epinephrine and cortisol responses, autonomic neuropathy, 
and alteration in glycogen metabolism (62,69,75,77).  
A defective glucagon counterregulatory system in T1D is associated with a number 
of serious health complications, the most catastrophic being severe hypoglycemia where 
the patient either loses consciousness or requires assistance. Hypoglycemia itself, even 
in milder forms (a BG<3.9 mmol/L), can lead to physical and/or psychosocial impairments, 
neuroglycopenia, cognitive dysfunction, and if left untreated can lead to brain damage, 
seizures, and in severe cases, death.  About 4-10% of deaths in T1D has been associated 
with hypoglycemia (17,75,80,82). Studies have shown that, defects in glucagon and 
catecholamine secretion in response to hypoglycemia is associated with at least a 25-fold 
increased risk of severe hypoglycemia in T1D (38,61,80,82). In healthy individuals, the 
detection of low BG in the brain and peripheral tissues, initiates the activation of a series 
of autonomic and endocrine responses that protect against hypoglycemia, including a 
decrease in insulin secretion and increases in glucagon, catecholamines, and cortisol 
secretion which counter insulin action (11). However, these lifesaving responses are 
impaired in individuals with T1D.  
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 Furthermore, antecedent hypoglycemia in T1D, caused by excessive insulin 
administration or by prolonged aerobic exercise, plays a major role in impairing the 
counterregulatory responses even more; thus, increasing the chances of future 
hypoglycemic episodes. Although the association of recurrent hypoglycemia, or simply 
repeated hypoglycemic episodes, and the development of counterregulatory impairments 
is well established, the underlying mechanisms are not fully understood.  
It has been shown that the over-production of SST in diabetes results in a 
significant reduction in circulating glucagon levels that prevent effective recovery from 
hypoglycemia (8,43,49,58). Hence somatostatin receptor type II antagonists (SSTR2a) 
are an attractive therapy to improve glucagon secretion during hypoglycemia (7–
9,17,57,58,87). In a series of in vivo experiments on rodents, it is shown that a newly 
developed SSTR2a, PRL-2903, improves the  glucagon response to hypoglycemia 
induced by either insulin or exercise (7–9,87). Additionally, basal glucagon secretion are 
two-fold higher in SSTR2 knockout mice (58,88). Although SSTR2a have been shown to 
improve the blunted glucagon response to hypoglycemia in T1D, the underlying 
mechanisms are not well understood.  
 The primary goal of this study is to determine the impact of a SSTR2a on plasma 
insulin and glucagon levels, and whether improvements in glucose production are 
associated with increased glycogenolysis in a non-diabetic model of counterregulatory 
failure. We hypothesize that the antagonism of SSTR2 on α-cells relieves the inhibitory 
effects of somatostatin on glucagon producing α-cells, thereby improving glucagon 
secretion and facilitating recovery from insulin-induced hypoglycemia. 
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Methods  
Ethics Statement 
This study is carried out in accordance with the recommendations of the Canadian 
Council for Animal Care guidelines and has been approved by the York University Animal 
Care Committee (Protocol # 2017-7). 
 
Rodent Treatment and Experimental Design 
For this protocol, we used a total of 35 healthy, non-diabetic, male Sprague-
Dawley (SD) rats (Charles River Laboratories, ~250g body mass post weaned) age ~ 9-
10 weeks old. Rats were housed in a light controlled (12-hour light/dark cycle) room with 
humidity of 50-60%, and temperature of 22-23oC. Rats had ad-libitum access to 
standard rodent chow (Purina Labdiet,5012, St. Louis, Missouri) and water. Animals 
were habituated to the vivarium for seven days and following this, body weight, BG, and 
food intake were monitored daily. After vivarium habituation, six rats were deeply 
anaesthetized with isoflurane prior to liver and muscle (tibialis anterior and extensor 
digitorum longus) sample collections. Then rats were subsequently euthanized via 
exsanguination.  
The remainder of the animals (n=29) underwent three consecutive days of 
recurrent insulin-induced hypoglycemia (BG target 1.7-2.2 mmol/L) to induce 
counterregulatory failure. Hypoglycemia was induced daily via intraperitoneal (IP) 
injection of insulin (Humulin-R, Lilly, Canada). It should be noted that all recurrent 
hypoglycemia events throughout the study occurred without an overnight fast, and with 
food temporarily removed prior to insulin administration (i.e. hypoglycemia induction). 
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The insulin dose was reduced with each day of treatment (10U/kg, 8U/kg, 5U/kg). This 
step-down reduction in insulin administration is performed in order to account for the 
loss in counterregulatory response that occurs even in healthy rodents with exogenous 
insulin treatment (89). Two recent studies have shown that a single 2-hour episode of 
mild hypoglycemia (3.1 mmol/L) reduces counter-regulatory endocrine responses to 
subsequent hypoglycemia up to 18-24 hours later (14,84). During the experimental 
phase of the protocol, BG concentrations were measured from a tail prick, using a hand-
held glucometer (AlphaTRAK, Abbott). BG was closely monitored every 10 minutes in 
all rats for 120 minutes post-insulin injection to make sure they stayed within the desired 
glycemic range of 1.7-2.2 mmol/L. However, if animals did not exhibit the expected fall 
in BG levels to hypoglycemia (< 3.0 mmol/L) after 60 minutes of the initial dose of 
insulin, they received another full dose of insulin. Alternatively, if animals dropped below 
the target range (1.7-2.2 mmol/L), 35% oral dextrose was given in small amounts (0.1-
1.0 mL) to bring BG levels back within the target range. Oral dextrose was administered 
either with a syringe for those rats that drank voluntarily, or through a feeding tube (oral 
gavage). If severe hypoglycemia developed (BG <1.0 mmol/L) or animal showed signs 
of distress such as seizures and convulsion, they received 1-2 ml dextrose (IP). In case 
of unsuccessful recovery (i.e. animal continued to showed signs of distress and/or BG 
stayed below the desired range), the experiment was stopped, and the animal was 
provided with food and/or sugar water to help recover blood glucose to a safe level 
(BG>4.5mmol/L). Upon completion of each hypoglycemic challenge, food was 
reintroduced (Fig.1). 
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The day following the recurrent hypoglycemia phase of the protocol, and prior to 
the last episode of hypoglycemia (i.e. hypoglycemia challenge), liver, tibialis anterior 
muscle, and extensor digitorum longus muscle samples from seven rats were collected 
under isoflurane anesthesia to investigate the impact of recurrent hypoglycemia on 
glycogen concentrations. Rats were then euthanized via exsanguination. 
On final day of the study (Day4), a subset of animals (n=22) were randomly 
assigned to receive either vehicle treatment (10mg/kg, 2% glycerol in water, IP) (n=9), 
or SSTR2a treatment (10mg/kg in 2 mL of vehicle solution of PRL2903, CDRD, 
Vancouver, Canada, IP) (n=13) one hour (t=-60 min) before hypoglycemia induction via 
insulin administration (5 U/kg Humulin R insulin, IP) (t= 0 min). BG was measured every 
10 minutes after insulin administration until the target BG of ≤3.5 mmol/L (i.e. clinical 
hypoglycemia) was reached. Rats were then anaesthetized with isoflurane for portal 
vein blood, liver, and muscle sample collection, before being euthanized via 
exsanguination (Fig.2) 
 
Plasma Analysis 
On the first and last days of recurrent hypoglycemia (Days 1 and 3, respectively), 
we performed repeat saphenous vein blood sampling just before insulin injection (t=0 
min), when BG reached 3.5 mmol/L, and at 60 minutes post-insulin treatment (t=+60 min). 
On the final day of the experiments (Day 4), blood samples were collected from a 
saphenous vein bleed once before drug/vehicle injections (t=-60 min), 1 hour later just 
prior to insulin injection (t=0 min), and immediately before euthanasia (at BG≤3.5 mmol/L) 
which was when the portal vein sampling also occured.  
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All blood samples were collected in potassium-EDTA coated microvette capillary 
tubes (Sarstedt, Des Grandes Prairies, Montreal, Québec, Canada, Cat #16.444.100), 
centrifuged at 12,000 rpm for 5 minutes and aliquoted into polyethylene tubes. All 
samples were preserved at -80oC to be used for the measurement of glucagon (Mercodia 
AB, Sweden, Cat# 10-1271-01), and insulin (C-peptide) (Crystal Chem, Downer’s Grove, 
Cat# 90055). 
 
Tissue Analysis 
Skeletal muscle (tibialis anterior and extensor digitorum longus) and liver 
samples were collected at baseline (right after vivarium habituation), as well as before 
and after the hypoglycemia challenge, either with or without the SSTR2a treatment for 
purpose of evaluating glycogen content (62,90). 
 
Statistical Analysis 
It should be noted that, one animal from the vehicle group was excluded from the 
data analysis as it was deemed to be resistant to hypoglycemia on the final day 
(hypoglycemia challenge) of the protocol. All data is analyzed using an appropriate t-test, 
and one-way ANOVA with a criterion of p<0.05. All significant differences for ANOVA 
testing will be evaluated using a Tukey post-hoc test (GraphPad Prism version 7.0). All 
data are mean ± SEM. 
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Results  
Glucagon counterregulation is attenuated by Day 3 of recurrent hypoglycemia. 
Basal and peak/hypoglycemic glucagon levels on the first and last days of 
recurrent hypoglycemia (Days 1 and 3), and on the final experimental day (Day 4) are 
shown in Figure 3. No differences were observed in basal glucagon levels between Day 
1 (21.63±2.86pg/ml) and Day 3 (20.62±2.12 pg/ml) of recurrent hypoglycemia, nor 
between the vehicle (11.59±1.78 pg/ml; n=9) and the SSTR2a (12.70±2.36 pg.ml; n=13) 
treated groups on experimental Day 4. Peak glucagon level during the recurrent 
hypoglycemic challenge on Day 3 was significantly lower than the values observed on 
Day 1 (107.49±10.27 pg/mL vs. 168.30±15.22 pg/mL; mean±SEM; p=0.0035), thereby 
confirming a significant loss in glucagon counterregulation over the three days of 
repeated exposure to hypoglycemia.  
The SSTR2a (PRL-2903) treatment improves glucagon counterregulation 
following three days of recurrent hypoglycemic.   
   Peak glucagon levels during hypoglycemia on Day 4 in the vehicle group 
(44.38±8.70 pg/ml) were significantly lower than on Day 1 (168.30±15.22 pg/ml; 
p<0.0001) and Day 3 (107±15.10.27 pg/ml; p=0.01), suggesting a further decline in 
glucagon counterregulation with time. In contrast, on Day 4, peak glucagon levels in the 
SSTR2a-treated group (109.38±15.37 pg/ml) were ~ 2.5-fold higher than in the vehicle 
group (P<0.01), similar to values observed on Day 3 of recurrent hypoglycemia (Fig.3).  
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SSTR2a pre-treatment delays the onset of hypoglycemia following an insulin 
overdose.  
Figure 4 shows the blood glucose concentrations on Days 1 and 3 of recurrent 
hypoglycemia and on experimental Day 4. Analysis of whole BG measurements using a 
handheld glucometer every 10 minutes post-insulin injection during the hypoglycemia 
challenge shows that SSTR2a-treated rats took ~3 times longer to develop 
hypoglycemia (i.e. BG≤3.5 mmol/L) as compared to controls (63.85±3.46 min vs. 
20±1.08 min, respectively, p=0.0098). Change in BG over the course of time for all fours 
days of the study is depicted in supplementary figure 1, which clearly illustrates the 
delayed hypoglycemia development in the experimental group. 
C-peptide levels during hypoglycemia are lower with SSTR2a treatment.  
C-peptide (pro-insulin connecting peptide) is a by-product of insulin biosynthesis 
and is produced in a 1:1 ratio with insulin, thereby giving a metric of endogenous insulin 
secretion in animals with functioning ß-cells (91). Figure 5 shows basal and 
hypoglycemic C-peptide values during Days 1 and 3 of recurrent hypoglycemia and on 
experimental Day 4. There were no significant differences in hypoglycemic C-peptide 
levels during Day 1 of recurrent hypoglycemia (0.85±0.11 ng/mL) and Day 3 (0.90±0.14 
ng/mL), however; levels dropped in the SSTR2a group on Day 4 (0.31±0.05 ng/mL) as 
compared to Day 1 (p=0.017) or Day 3 (p=0.008). Values in the vehicle group also 
tended to decline on Day 4 (0.63±0.07 ng/mL), as compared to the recurrent 
hypoglycemia phase, but this drop failed to reach statistical significance.  
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Recurrent hypoglycemia has no impact on skeletal muscle glycogen stores, but 
SSTR2a significantly increases hepatic glycogen depletion.  
Figure 6 shows no difference in hepatic glycogen levels between baseline (Day 
1) and after 3 days of recurrent hypoglycemia (i.e. just before the fourth hypoglycemic 
challenge).  However, hepatic glycogen levels were significantly lower with the SSTR2a 
treatment compared to vehicle (Glycogen: 11.77±1.41µmol; n=13 vs. 20.66±2.34 µmol; 
p=0.001). No significant difference was observed in tibialis anterior muscle and extensor 
digitorum longus muscle glycogen levels throughout the study (Supplementary Fig.2-3). 
Corticosterone levels are not likely to be impacted by SSTR2a treatment. 
Corticosterone was measured only in a subset of animals. Corticosterone levels 
during hypoglycemia on Day 4 were similar between SSTR2a treated (536.65±60.50 
ng/ml; n=6) and vehicle treated (673±58.15 ng/ml; n= 3) rats (Supplementary Fig.4). 
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Discussion 
The association between recurrent hypoglycemia, and failure of the endocrine 
and sympathoadrenal responses to hypoglycemia in T1D  has been well established  
(82–84,88). In the current study, we showed that glucagon counterregulatory responses 
in healthy, non-diabetic rats can be markedly attenuated with each hypoglycemia event 
in as little as 3-4 days. These findings reiterate the negative consequences of 
hypoglycemia per se on α-cells function with regards to insulin-to-glucagon dynamics, 
and in turn, glucose production which appears to be independent of diabetes itself. We 
also showed that SSTR2a can partially restore the glucagon response to hypoglycemia 
(BG≤ 3.5 mmol/L) in recurrently hypoglycemic animals with overt counterregulatory 
failure. This improvement in glucagon secretion was accompanied by reduced insulin 
secretion (i.e. lower C-peptide levels), and hepatic glycogen levels which likely 
translates into greater hepatic glucose output, in the SSTR2a treated group compared 
to the vehicle.  
A balance between the main glucoregulatory hormones insulin and glucagon is 
required to maintain blood glucose levels within a narrow range during periods of 
fasting, feeding, and physically activity (1). Dysregulation of either insulin or glucagon, 
as is the case in T1D, causes metabolic dysregulation that ranges from severe 
hyperglycemia when there is relative hypoinsulinemia and hyperglucagonemia, to 
severe hypoglycemia which stems from relative excess insulin in the face of 
counterregulatory failure (lack of glucagon and epinephrine). Hypoglycemia is 
associated with 4-10% of deaths in T1D (17,74,79,81), and episodic and recurrent 
hypoglycemia in T1D is a major clinical barrier to maintaining good glycemic control in 
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diabetes as it sets the stage for a severe or catastrophic event. Defects in glucagon 
secretion with prolonged diabetes are associated with at least a 25-fold increased risk of 
severe hypoglycemia (10,30,80). This phenomenon is observed in both rodents 
(34,60,92) and humans (12,30,80,81,84) with diabetes, but is not necessarily unique to 
diabetes (83,92). Glucagon responses were reduced by 84% in non-diabetic rats made 
recurrently hypoglycemic over the course of four weeks (92). Results from our study 
show that, this recurrent hypoglycemia protocol can effectively impair the glucagon 
response to hypoglycemia in healthy, non-diabetic rats. Analysis of plasma glucagon 
concentrations from saphenous vein samples show that, peak glucagon levels on the 
final day (Day 3) of recurrent hypoglycemia are 57% lower compared to the first day 
(Fig.3); with no differences observed in basal glucagon levels. Hence, repeated 
episodes of insulin-induced hypoglycemia can cause short-term imbalances in 
glucagon-insulin dynamics that can negatively impact glucagon counterregulation, even 
in healthy animals. 
Additionally, our data demonstrates that PRL-2903, a SSTR2a, can improve the 
blunted glucagon response in recurrently hypoglycemic animals and delay the onset of 
hypoglycemia. Somatostatin secreted from pancreatic δ-cells is a major paracrine 
inhibitor of insulin and glucagon under conditions of hypo- and hyperglycemia, 
respectively (29,49). In rodents, α-cells are generally more sensitive to the inhibitory 
effects of SST than β-cells (6,49), which could possibly be due to closer spatial 
association between δ-cells and α-cells which creates a more direct cell-cell contact (6). 
Studies suggest that over-production of SST in diabetes may be one factor contributing 
to a blunted glucagon response to hypoglycemia (8,43,49,58). In both healthy, non-
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diabetic humans and animals where β-cells are intact, SST may have minimal inhibitory 
effects on glucagon producing α-cells because of its dominant role in β-cell (insulin) 
inhibition, whereas in T1D, SST paracrine inhibition of α-cells arises from the absence of 
β-cells (7,80,82).  
 In rodents, PRL-2903 improves the glucagon response to hypoglycemia induced 
by insulin administration or by exercise (7–9). Additionally, glucagon secretion is two-fold 
greater in SSTR2 knockout mice, suggesting SSTR2 may be an effective therapeutic 
target to augment glucagon secretion (58). This is consistent with our data showing 
SSTR2a treatment increases glucagon responses by ~2.5-fold which likely contributed to 
delaying the development of hypoglycemia by 3.2-fold in recurrently hypoglycemic 
animals. Improvements in glucagon secretion with SST antagonism also increased the 
mobilization of glucose into circulation as evidenced by the reduction of liver glycogen 
content which was likely responsible for delaying the onset of hypoglycemia (69). We 
thought that the inability to recover from hypoglycemia in both diabetic and non-diabetic 
models could be due to depletion of glycogen stores as a result of repeated exposure to 
hypoglycemia (53, 60). Surprisingly, analysis of hepatic glycogen content in this study 
shows that, recurrent hypoglycemia does not affect hepatic glycogen storage levels. This 
may be the result of impairments in glycogenolytic capacity in the setting  of 
counterregulatory failure (62). Alternatively, the lack of difference in hepatic glycogen 
levels during recurrent hypoglycemia could be due to its full restoration to normal levels 
due to plasma increased glucose and insulin levels after food intake which stimulate 
glycogen synthesis. However, hepatic glycogen levels in the SSTR2a treated group are 
47% lower than the vehicle group after hypoglycemia exposure on the final (Day 4) 
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experimental day. This novel finding indicates that, lower hepatic glycogen levels in the 
PRL-2903-treated group is possibly the result of  a more robust glucagon response that 
enhances glycogenolytic capacity (62). Also, SSTR2a may be indirectly suppressing 
insulin secretion and hence, less effective glycogen deposition. No differences were 
observed in tibialis anterior and extensor digitorum longus glycogen levels either with or 
without SSTR2a treatment.  This is likely due to the lack of glucagon receptors in muscle. 
Mobilization of muscle glycogen stores is predominantly mediated by epinephrine during 
exercise, and the produced glucose is used locally, not systematically. Therefore, even 
though most glycogen is stored in skeletal muscle (68), muscle glycogen breakdown 
mainly provides energy locally during high intensity exercise (30,68). However, no 
differences in muscle glycogen levels is an important observation, as it highlights the 
specific effects of SSTR2a on glucagon responses specifically, and not other 
counterregulatory mechanism such as improvement in epinephrine secretion.    
Another novel finding of this study is the observation of lower C-peptide levels in 
the SSTR2a group compared to the vehicle group during hypoglycemia on experiment 
Day 4. The C-peptide results contradict our hypothesis which anticipated no significant 
difference in insulin secretion with or without SSTR2a treatment. Interestingly, C-peptide 
levels are significantly lower in the SSTR2a treated group compared to vehicle during 
hypoglycemia on Day4. Studies have shown that, although SST inhibits both glucagon 
and insulin; it predominantly inhibits insulin secretion when β-cells are intact (7,80,82). 
Therefore, in the presence of SSTR2 antagonist, there may be more free SST available 
for binding to SSTRs on β-cells which could explain the lower insulin levels in the 
SSTR2a treated group. Moreover, higher glucagon levels during hypoglycemia in the 
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treatment group could also result from lower insulin levels as glucagon is a paracrine 
inhibitor of insulin secretion under conditions of hypoglycemia (1,20,93). Therefore, 
inhibitory actions of SST along with higher levels of glucagon (i.e. better glucagon 
counterregulation) leads to a greater inhibition on insulin secretion, and in turn lower 
insulin levels with SSTR2a treatment during hypoglycemia.  
 Hypoglycemia activates the hypothalamo-pituitary-adrenal (HPA) axis which 
regulates the secretion of glucocorticoids (76). Glucocorticoids aid in the recovery from 
more prolonged and/or more severe hypoglycemia (83,84,92). In rats, corticosterone is 
the active glucocorticoid. In general, recurrent insulin-induced hypoglycemia activates 
the HPA (hypothalamic, pituitary, adrenal axis) which regulates secretion of 
glucocorticoids and epinephrine (76). Thus, hypoglycemia induced increase in 
corticosterone levels can facilitate recovery from hypoglycemia (2,85,94).We looked at 
corticosterone levels in about half of the animals (n=10), but there was no significant 
difference between the SSTR2a and the vehicle group. This may be an indication that 
the antagonist only targets the endocrine pancreas, and more specifically, the α- and ß-
cells, rather than whole body counterregulatory systems. However, studies looking at 
effects of SSTR2a on counterregulatory responses to hypoglycemia in STZ diabetic 
models show improvement in both glucagon and corticosterone counterregulatory 
responses (8,9) 
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Conclusion 
In conclusion, we showed that SST antagonism with PRL-2903 may be an 
effective way to improve glucagon secretion following recurring exposure to 
hypoglycemia. This improvement appears to be associated with a reduction in insulin 
secretion and increased hepatic glycogenolysis. As somatostatin normally inhibits 
glucagon and its levels are abnormally high in T1D diabetes, SSTR2a treatment may be 
a useful therapeutic approach to improve glucagon responses to insulin and/or exercise 
induced hypoglycemia in patients with T1D. This treatment would facilitate a better 
glycemic control for patients with T1D without the fear of hypoglycemia. 
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Figures  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Experimental timeline: Recurrent hypoglycemia period (Days 1-3). 
Twenty-two (n=22) male Sprague-Dawley rats underwent three consecutive days of 
repeated insulin-induced hypoglycemia with 10-, 8-, and 5-U/kg of Humulin-R insulin on 
Days 1-3, respectively, to induce moderate to severe hypoglycemia (1.7-2.2 mmol/L) for 
up to 120 minutes. Blood samples were collected from the saphenous vein at baseline 
(time=0 min), at BG ≤ 3.5 mmol/L (i.e. clinical hypoglycemia), and 60 minutes post 
insulin injection for the determination of plasma glucagon and C-peptide levels. 
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Figure 2. Experimental timeline: Experimental hypoglycemic challenge with or 
without SSTR2a treatment (Day 4). One hour prior to the last episode of insulin-
induced hypoglycemia (time= -60 min), animals were randomly assigned to the SSTR2a 
treatment group (n=13) or a vehicle control group (n=9). All animals received an IP 
injection of Humulin-R insulin (5U/kg) 60 minutes after drug or vehicle administration 
(time=0 min). Blood glucose levels were assessed at baseline (time=-60 min, just before 
drug or vehicle administration), 30-minutes post drug/vehicle administration (time=-30 
min), just prior to insulin administration (time=0 min), and every 10 minutes after that 
until the end of the protocol (defines asBG≤ 3.5 mmol/L). Saphenous vein samples were 
collected at baseline, prior to insulin administration, and at the onset of hypoglycemia 
for the determination of plasma glucagon, C-peptide and corticosterone levels.  
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Figure 3. Baseline and peak (hypoglycemic) glucagon levels. Basal vs 
hypoglycemic glucagon concentrations (pg/mL) during the recurrent hypoglycemia 
phase (Day 1 and Day 3; n=22), and challenge day (Day 4) either with (n=13) or without 
(n=9) the SSTR2a (PRL2903) pre-treatment. Note: *,**,***,**** indicates significance 
compared to Peak/D1 P<0.05, 0.01, 0.001, 0.0001 respectively; #, indicates significance 
compared to Peak/D3 ; +, indicates significance compared to Vehicle. Inset: 
Comparison of peak glucagon responses during the hypoglycemia challenge on Day 4. 
All data is presented as mean±SEM.   
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Figure 4. Time to reach hypoglycemia with and without SSTR2a treatment. Time 
(min) to development of hypoglycemia (BG≤3.5 mmol/L) for the SSTR2a (n=13) the 
vehicle groups (n=9) (p=0.001). Data is presented as mean ± SEM.  
		
56	
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Baseline and nadir (hypoglycemic) C-peptide levels. Basal vs nadir 
(hypoglycemic) C-peptide concentrations (pg/mL) during the recurrent hypoglycemia 
phase (n=22), and challenge day with (n=13) or without (n=9) the SSTR2a (PRL2903) 
pre-treatment. Note: *,**,***,**** indicates significance compared to Peak/D1 P<0.05, 
0.01, 0.001, 0.0001 respectively; #, indicates significance compared to Peak/D3 ; +, 
indicates significance compared to Vehicle. Inset: Comparison of C-peptide levels 
during the hypoglycemia challenge on Day 4. Data is presented as, mean ± SEM.  
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Figure 6. Hepatic (liver) glycogen levels. Baseline (day 0) represents normal hepatic 
glycogen levels in healthy rats that were sacrificed right after the habituation period (i.e. 
no hypoglycemia exposure). Pre-hypo is after three days of recurrent hypoglycemia but 
no hypoglycemia challenge. Post hypo, Vehicle and SSTR2a is after hypoglycemia 
challenge on day 4. Note: *,**,***,**** indicates significance compared to baseline (day 
0); P<0.05, 0.01, 0.001, 0.0001 respectively; #, indicates significance compared to pre-
hypo  ; +, indicates significance compared to post-hypo, Vehicle. Data is presented as, 
mean ± SEM.  
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Summary 
In summary, we show in this study that three days of recurrent hypoglycemia 
dramatically attenuates the glucagon response to hypoglycemia. We see that the 
administration of a SSTR2a can improve glucagon counterregulation, lower 
endogenous insulin secretion and increase hepatic glycogen breakdown during 
hypoglycemia, and dramatically increase the time before hypoglycemia onset following 
exogenous insulin administration in healthy male Sprague-Dawley rats. These findings 
support a growing body of evidence that SSTR2a treatment may have clinical benefit for 
patients living with diabetes who have frequent episodes of hypoglycemia caused by 
insulin therapy and or regular physical actively. 
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Limitations and Future direction 
In this study, we wanted to investigate the impact of SSTR2a on glucagon and 
other counterregulatory pathways/factors to learn more about the pathophysiology of 
the drug. Therefore, we looked at corticosterone as a non-pancreatic regulator of BG 
and counterregulatory responses. Due to inadequate amount of plasma samples, we 
were not able to look at corticosterone levels in all animals, and throughout the 
recurrent hypoglycemia phase of the study. Corticosterone was only measure in ten 
animals, and only during the final experimental day (Day 4). Since the corticosterone 
data collected from those rats didn’t show any trends of difference between the SSTR2a 
treated and the vehicle groups, we decided to save the remainder of the plasma, from 
the remainder of animals, for SST measurement as it is a major inhibitory regulator of 
both insulin and glucagon, and plays a major role in counterregulatory responses to 
hypoglycemia. Having a low n-value for both the treatment and the control group could 
be the reason why we didn’t see any trends in the corticosterone data. Other than 
looking at the impact of SSTR2a on corticosterone, it would be interesting to look at the 
effects of repeated hypoglycemia on baseline and peak corticosterone levels.  
SST levels were measured using ELISA assays, but the data is excluded from 
the study as the assays used had gone bad because of improper handling during 
shipment, so the collected data is not reliable.   
All hormones, including glucagon, insulin, SST, and corticosterone were 
measured in peripheral (saphenous) as well as portal circulation, but portal vein data is 
excluded due to use of expired EDTA for portal vein collection. The data is significantly 
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variable, and unreliable. It would be interesting to compare hormonal levels in portal and 
peripheral circulation as pancreatic hormones bypass the liver before entering the 
peripheral circulation. Additionally, the antagonist treated animals show an interesting 
pattern of blood glucose fluctuations overtime. However, we don’t clearly know what 
exactly happens to plasma glucagon and insulin levels during Day 4 as we only 
measured insulin and glucagon at the beginning and at the end of the experiment (i.e. at 
baseline and at the onset of hypoglycemia). Whether or not the changes in peripheral 
insulin and glucagon concentrations during the final hypoglycemic event reflect the 
same pattern as plasma glucose remains a question. 
In the future, we are hoping to replicate this study addressing all the limitations 
mentioned above, and introduce more variables such as diabetes, sex and age 
differences, and method of substance (insulin/SSTR2a) administration (IP vs 
Subcutaneous) to the current model to amplify the importance of our current findings, 
and hopefully make them clinically applicable.  
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Appendix A: Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. A) Change in blood glucose over time. Blood glucose 
changes for all animals (n=22) during recurrent hypoglycemia, and hypoglycemia 
challenge with (n=13) and without (n=9) SSTR2a treatment. B) Area under the curve 
(AUG) for the pooled blood glucose change over time. Data is presented as, 
Mean±SEM.  
A) 
B) 
		
71	
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Tibialis anterior glycogen levels. Baseline (day 0) 
represents normal skeletal glycogen levels in healthy rats that were sacrificed right after 
the habituation period (i.e. no hypoglycemia exposure). Pre-hypo is glycogen levels 
after three days of recurrent hypoglycemia but no hypoglycemia challenge, and Post 
hypo, Vehicle and SSTR2a, is after hypoglycemia challenge on day 4. Data is 
presented as, mean ± SEM. 
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Supplementary Figure 3. Extensor Digitorum Longus glycogen levels. Baseline 
(day 0) represents normal skeletal glycogen levels in healthy rats that were sacrificed 
right after the habituation period (i.e. no hypoglycemia exposure). Pre-hypo is glycogen 
levels after three days of recurrent hypoglycemia but no hypoglycemia challenge, and 
Post hypo, Vehicle and SSTR2a, is after hypoglycemia challenge on day 4. Data is 
presented as, mean ± SEM. 
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Supplementary Figure 4. Corticosterone concentrations with and without SSTR2a 
treatment. Corticosterone levels on hypoglycemia challenge day (i.e. final day of 
insulin-induced hypoglycemia) at baseline (before treatment administration; time=-60 
min), and at hypoglycemia (BG≤3.5 mmol/L) in saphenous vein collections. Data is 
presented as, mean ± SEM. 
 
 
 
 
 
